Solid Tumor 1238 Gene Testing for Comprehensive Profiling

Overview

A 1238-gene solid tumor panel reaches near-whole-exome breadth while keeping turnaround practical for clinical use. This breadth lets the laboratory see both common drivers and uncommon alterations that narrow panels miss. Comprehensive profiling suits advanced cases where every actionable signal carries weight. Clinicians order it when a narrower test already returned no actionable result.

How It Works

Hybrid capture enriches more than a thousand genes in a single library from one extracted sample. Sequencing reads map to the genome and are jointly analyzed for mutation, copy change, and fusion. Depth is tuned per gene so both hot spots and rare loci receive adequate calls. Machine-assisted annotation ranks findings by therapeutic and trial evidence level. A secondary germline filter separates inherited variants from tumor-acquired changes. Coverage includes intronic regions relevant to splice variants that small panels omit.

Indications

Advanced disease with no remaining standard option gains from the widest possible target search. Young patients with suggestive family history may uncover hereditary syndromes during analysis. Tumors that failed narrower testing are revisited with the expanded gene footprint. Tumors with ambiguous histology benefit from the wide footprint to suggest tissue origin.

Specimen Requirements & Reporting

Reports usually post within twelve business days of specimen acceptance at the facility. The output groups somatic drivers, resistance hints, and trial matches in labeled sections. Clinicians may request a curated summary focused only on guideline-listed genes. FFPE blocks stored beyond a year are still accepted if nucleic quality passes the screen.

Storage & Sourcing

Raw sequence data is archived under encrypted storage for the retention period stated in consent. Specimens travel in validated packaging with continuous temperature documentation. Health systems ordering at scale receive API delivery of structured results. Access to raw data supports later re-annotation as new evidence emerges.

FAQ

Q: How does whole-exome-scale sequencing differ from small panels? A: The wide footprint captures uncommon drivers and fusions that a focused panel would omit, at the cost of longer reporting.

Q: What bioinformatics pipeline supports the 1238-gene report? A: A joint mutation, copy-number, and fusion pipeline annotates each finding by evidence tier for the clinician.

Q: Are germline findings separated from somatic calls? A: A dedicated germline filter distinguishes inherited variants so they are not mistaken for tumor-acquired changes.

Q: What turnaround applies to the 1238-gene test? A: Results typically post within twelve business days after the laboratory accepts a quality-passed specimen.